Nguyen Duy Toan, Dao Bui Quy Quyen, Nguyen Duc Loc, Ho Viet Le Diem, Le Ha Khoa, Do Gia Tuyen, Nguyen Trung Kien, Nguyen Van Tam, Nguyen Oanh Oanh, Le Viet Thang
Military Hospital 103, Hanoi, Vietnam.
Vietnam Military Medical University, Hanoi, Vietnam.
Int J Gen Med. 2023 Oct 4;16:4525-4535. doi: 10.2147/IJGM.S426670. eCollection 2023.
To evaluate the value of contrast volume/glomerular filtration ratio (Vc/eGFR ratio) and urine Neutrophil Gelatinase-Associated Lipocalin (uNGAL) in predicting the progression contract associated-acute kidney injury (CA-AKI) to chronic kidney disease (CKD) in planned percutaneous coronary intervention (PCI) patients.
We examined 387 adult patients who had undergone planned percutaneous coronary intervention (PCI). We determined acute kidney injury (AKI) and chronic kidney disease (CKD) using the criteria set by the Kidney Disease: Improving Global Outcomes (KDIGO). We calculated the estimated glomerular filtration rate (eGFR) using the CKD-EPI formula based on serum creatinine levels. To determine the Vc/eGFR ratio, we considered the contrast medium volume and eGFR for each patient. Additionally, we measured urine NGAL levels using the ELISA method.
The percentage of CA-AKI patients who developed CKD after planned PCI was 36.36%. Within the CA-AKI to CKD group, the Vc/eGFR ratio was 2.82, and uNGAL levels were significantly higher at 72.74 ng/mL compared to 1.93 ng/mL for Vc/eGFR ratio and 46.57 ng/mL for uNGAL in the recovery CA-AKI group. This difference was statistically significant (p<0.001). Diabetic mellitus, urine NGAL concentration, and Vc/eGFR ratio were found to be independent factors in the progression of CA-AKI to CKD. The Vc/eGFR ratio and uNGAL showed predictive capabilities for progressing CA-AKI to CKD with an AUC of 0.884 and 0.878, respectively. The sensitivity was 81.3% for both, while the specificity was 89.3% for Vc/eGFR ratio and 85.7% for uNGAL.
The Vc/eGFR ratio and uNGAL were good predictors for CA-AKI to CKD in planned PCI patients.
评估对比剂用量/肾小球滤过率(Vc/eGFR比值)和尿中性粒细胞明胶酶相关脂质运载蛋白(uNGAL)在预测择期经皮冠状动脉介入治疗(PCI)患者中对比剂相关急性肾损伤(CA-AKI)进展为慢性肾脏病(CKD)方面的价值。
我们检查了387例接受择期经皮冠状动脉介入治疗(PCI)的成年患者。我们使用改善全球肾脏病预后组织(KDIGO)制定的标准来确定急性肾损伤(AKI)和慢性肾脏病(CKD)。我们根据血清肌酐水平使用CKD-EPI公式计算估算肾小球滤过率(eGFR)。为了确定Vc/eGFR比值,我们考虑了每位患者的对比剂用量和eGFR。此外,我们使用ELISA方法测量尿NGAL水平。
择期PCI后发生CKD的CA-AKI患者比例为36.36%。在CA-AKI至CKD组中,Vc/eGFR比值为2.82,uNGAL水平显著更高,为72.74 ng/mL,而恢复性CA-AKI组的Vc/eGFR比值为1.93 ng/mL,uNGAL为46.57 ng/mL。这种差异具有统计学意义(p<0.001)。发现糖尿病、尿NGAL浓度和Vc/eGFR比值是CA-AKI进展为CKD的独立因素。Vc/eGFR比值和uNGAL对CA-AKI进展为CKD具有预测能力,AUC分别为0.884和0.878。两者的敏感性均为81.3%,而Vc/eGFR比值的特异性为89.3%,uNGAL的特异性为85.7%。
Vc/eGFR比值和uNGAL是择期PCI患者中CA-AKI进展为CKD的良好预测指标。